The Effect of Tunicamycin on Interferon-a Production in a Human
Lymphoblastoid Cell Line (Namalwa) (Accepted 1 June 1982) SUMMARY Tunicamycin alters the biological properties of human interferon-c~ (HuIFN-a) produced in its presence by changing the mixture of IFN-a subtypes produced. When IFN mRNA extracted from treated cells was microinjected into oocytes the product was also altered. However, treatment of the oocytes with tunicamycin did not alter the properties of the IFN-a produced.
Different experimental approaches have been used to determine whether human interferon (HulFN) is glycosylated (for review, see Stewart, 1979) . HulFN-a produced in the presence of tunicamycin, an antibiotic that inhibits N4inked glycosylation (Schwarz & Datema, 1980) , was shown to have higher activity on heterologous cells and to have a lower apparent molecular weight (Chadha et aL, 1980) . These results were interpreted as demonstrating that HulFN-a was glycosylated via an N-linkage.
However, this conclusion now has to be re-evaluated with the detailed knowledge of the molecular structure of the various HulFN-a subtypes. Indeed, the amino acid sequences, predicted from the nucleotide sequences of the cloned genes (Nagata et al., 1980; Goeddel et al., 1981) , or determined directly on pure IFN-ct (Allen & Fantes, 1980) , do not contain sites for N-linked glycosylation. Furthermore, no amino sugars were detected in a pure preparation of IFN-ct (Allen & Fantes, 1980) . Here I report a study of the effects of tunicamycin on IFN-ct production and demonstrate that the antibiotic alters the expression of IFN-a species at the transcriptional level.
Ceils, virus and conditions for induction of Namalwa cells were as described elsewhere (Allen et aL, 1982) . Tunicamycin, a kind gift from Dr R. L. HamiU of Eli Lilley, U.S.A., was dissolved in dimethyl sulphoxide at 1 mg/ml and stored at -20 °C. When used, it was included in the induction medium at 1 ltg/ml from 1 or 3.5 h after induction. Under these conditions we detected no inhibition of protein synthesis. IFN samples were collected and assayed as described by Allen et al. (1982) . RNA was extracted by the guanidinium isothiocyanate technique (Morser & Shuttleworth, 1981) and assayed by microinjection into oocytes (Colman & Morser, 1979) . The procedures for purification and analysis of IFN-a were described by Allen et al. (1982) .
Namalwa cells were induced with Sendal virus, and 1 h later tunicamycin was added. The IFN was collected after 24 h and assayed on both human and bovine cells. Compared with a control preparation of IFN from untreated cells, there was more activity on bovine (EBTr) cells although the titre on human (HFF) cells was unaltered by treatment (Table 1 ). The mass of IFN-cz synthesized by treated or control cells was the same when it was measured by an immunoradiometric method (Secher, 1981) . Thus, treated and control cells were producing the same amount of IFN but the treatment with tunicamycin was altering its properties. The change in properties was observed at all time points after addition of tunicamycin, and also if the tunicamycin was added at 3.5 h rather than 1 h after induction. The antibiotic was probably not affecting secretion because the intracellular IFN also displayed the anomalously high activity on bovine cells (data not shown).
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t mRNA was extracted 9 h after induction and injected into 10 oocytes, and the resultant secreted IFN was titrated. The oocytes were treated with tunicamycin as described by Colman et al. (1981) .
investigated by purifying a sample of the IFN prepared in the presence of tunicamycin by chromatography on a polyclonal antibody column followed by the steps described by Fantes et al. (1980). The purified IFN was then analysed by gel filtration on Sephadex G-75. A control sample of IFN was purified and analysed in parallel and the results are shown in Fig.  1 (a) . The control preparation was resolved into two peaks (A and B). This contrasted with the results from IFN produced in the presence of tunicamycin, in which peak A was much reduced while peak B was broader (Fig. 1 b) when the activity was assayed on bovine, human or monkey cells. However, when the activity was titrated on mouse cells, a single sharp peak at fraction number 53 was observed. This method of analysis partially resolves the different molecular subtypes of IFN-a and the results suggest that the IFN synthesized in the presence of tunicamycin is composed of a different mixture from control IFN (Allen et aL, 1982) .
If the tunicamycin was acting at a translational or post-translational step in the production of IFN, then treatment of oocytes that had been microinjected with IFN mRNA would be expected to produce IFN with the altered properties. However, when this experiment was carried out under conditions in which tunicamycin has been shown to be active in oocytes (Colman et aL, 1981) , no alteration in the ratio of IFN activity in bovine cells to that in human cells was observed (Table 1) . However, when IFN mRNA was extracted from tunicamycin-treated cells and injected into oocytes, it directed the synthesis of material with the altered properties (Table 1) . Thus, the alteration in properties appears to be encoded in the mRNA.
All samples in Table 1 were tested for neutralization by anti-HulFN-tz and by anti-HulFN-fl sera. The anti-IFN-cz serum completely neutralized all of them but the anti-IFN-fl serum had no effect, demonstrating that the IFN produced in the presence of tunicamycin did not have an altered ratio of IFN-a to IFN-fl.
The results reported here show that the IFN produced by Namalwa cells in the presence of tunicamycin has altered properties. I attribute this effect to changes in the mixture of IFN-a subtypes expressed, which are in turn determined by changes in the IFN mRNA transcribed in treated cells. This makes it unlikely that the antibiotic is acting on glycosylation in this system; rather, it has a direct or indirect effect on transcription.
